Visualizing vitreous in vitrectomy by triamcinolone

BACKGROUND

Visualizing vitreous and retinal surface during vitrectomy, choromovitrectomy, is a novel approach in vitrectomy.

METHODS

Triamcinolone acetonide (TA) is now most commonly used as an adjunct to vitrectomy for this purpose. Intraoperative use of TA can visualize posterior hyaloid, preretinal membrane, internal limiting membrane (ILM) during pars plana vitrectomy, and prolapsed vitreous during cataract surgery, which can make the procedure very safe and effective. TA-assisted vitrectomy is favorably applied to surgery for macular hole, proliferative vitreoretinopathy, diabetic retinopathy, uveitis, and others. In addition, this technique can disclose the residual hyaloid cortex pattern after surgical posterior vitreous detachment. Diffuse posterior hyaloids cortex is frequently seen in diabetic retinopathy and high myopia, and an island-like cortex is often left on the macula, which can be a scaffold of future macular pucker.

RESULTS

The prospective controlled clinical trial showed that TA-assisted vitrectomy reduced the incidence of intraoperative retinal break and retinal detachment more significantly than conventional vitrectomy, although post-operative visual acuity after 1 year was almost the same with each method. Adverse events related to TA-assisted vitrectomy included transient intraocular pressure elevation (approximately 5.0%); most of these events are manageable with topical treatment. The incidence of acute endophthalmitis was 0.03-0.05% , which was at a level comparable to conventional vitrectomy.

CONCLUSIONS

In this article, current status and the possible problems of TA-assisted vitrectomy are reviewed.

Intravitreal triamcinolone acetonide injection in blind painful eyes. Intraocular steroids as a treatment for blind painful red eyes

PURPOSE

Phthisis bulbi results from different ocular conditions. We evaluated intravitreal triamcinolone acetonide as a treatment option in blind painful eyes.

METHODS

Thirty-one patients with unilateral phthisis were randomly divided into two groups. Group A received 0.3 ml (12.5 mg) triamcinolone acetonide intravitreally and Group B 0.3 ml balanced salt solution after retrobulbar anesthesia. Treatment success was assessed by subjective response to pain and clinically by biomicroscopic evaluation of conjunctival congestion. Tonometry was done before and after treatment. Follow-ups were at 24 hours, 3 weeks, 3 and 6 months, and 1 and 2 years.

RESULTS

Throughout the two-year follow-up, only two patients in Group A reported pain after the procedure and were retreated, one at week 4 and the other at week 7. Conjunctival congestion was significantly lower in Group A. Two patients with hypotony before treatment had normal tension after triamcinolone. All Group B patients were reinjected with triamcinolone because pain continued after balanced salt solution injection. No severe complications were found.

CONCLUSIONS

Intravitreal triamcinolone acetonide may be effective and safe for treating blind painful eyes.

Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy

PURPOSE

To report the clinical outcome and complications of intravitreal injections of crystalline cortisone in patients undergoing pars plana vitrectomy for treatment of proliferative diabetic retinopathy.

METHODS

The prospective, interventional case series study included 29 consecutive patients (29 eyes) who underwent pars plana vitrectomy for treatment of complicated proliferative diabetic retinopathy associated with central retinal traction detachment. All patients received an intravitreal injection of 15 to 20 mg of crystalline triamcinolone acetonide at the end of surgery, and were operated on by the same surgeon. Mean follow-up time was 1.4 +/- 1.1 months (median, 1 month; range, 0.30 to 4.9 months).

RESULTS

At the end of the follow-up period, the retina was attached in 26 of the 29 patients (89.7%). In three of the 29 patients (10.3%), a retinal redetachment had occurred. None of the patients developed iris neovascularization, and the iris neovascularization, present preoperatively in 12 patients, slightly to markedly regressed in all 12 patients. Preoperative and postoperative intraocular pressure values (P =.72) and blood glucose measurements did not vary significantly. A pseudohypopyon consisting of cortisone crystals in the inferior anterior chamber angle was detected in one patient and resolved spontaneously within 4 days.

CONCLUSIONS

The present clinical study suggests that intravitreal injection of crystalline cortisone with most of the vehicle removed seems to be well tolerated by eyes undergoing pars plana vitrectomy for treatment of complicated diabetic proliferative retinopathy. In view of the antiphlogistic and antiproliferative effect of cortisone, future randomized clinical trials may be indicated to investigate further the role of intravitreal injection of crystalline cortisone in the treatment of proliferative diabetic retinopathy.